Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RP 72

Next Previous
Drug Profile

RP 72

Alternative Names: Rise Prot-72; RP-72

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rise Biopharmaceuticals
  • Class Antineoplastics; Chemokines; Immunotherapies; Recombinant proteins; Small molecules
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pancreatic cancer

Most Recent Events

  • 28 May 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Taiwan (IV, Injection)
  • 28 May 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in Taiwan (IV, Injection)
  • 19 Apr 2021 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Taiwan (IV) (NCT04338763)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top